NO312397B1 - Enteriske duloxetinpellets - Google Patents

Enteriske duloxetinpellets Download PDF

Info

Publication number
NO312397B1
NO312397B1 NO19952786A NO952786A NO312397B1 NO 312397 B1 NO312397 B1 NO 312397B1 NO 19952786 A NO19952786 A NO 19952786A NO 952786 A NO952786 A NO 952786A NO 312397 B1 NO312397 B1 NO 312397B1
Authority
NO
Norway
Prior art keywords
duloxetine
layer
enteric
suspension
product
Prior art date
Application number
NO19952786A
Other languages
English (en)
Norwegian (no)
Other versions
NO952786L (no
NO952786D0 (no
Inventor
Neil Robert Anderson
Peter Lloyd Oren
Toshihiro Ogura
Toshiro Fujii
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23055767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO312397(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of NO952786D0 publication Critical patent/NO952786D0/no
Publication of NO952786L publication Critical patent/NO952786L/no
Publication of NO312397B1 publication Critical patent/NO312397B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
NO19952786A 1994-07-18 1995-07-13 Enteriske duloxetinpellets NO312397B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/276,232 US5508276A (en) 1994-07-18 1994-07-18 Duloxetine enteric pellets

Publications (3)

Publication Number Publication Date
NO952786D0 NO952786D0 (no) 1995-07-13
NO952786L NO952786L (no) 1996-01-19
NO312397B1 true NO312397B1 (no) 2002-05-06

Family

ID=23055767

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19952786A NO312397B1 (no) 1994-07-18 1995-07-13 Enteriske duloxetinpellets
NO2005002C NO2005002I2 (no) 1994-07-18 2005-02-01 Duloksetin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2005002C NO2005002I2 (no) 1994-07-18 2005-02-01 Duloksetin

Country Status (30)

Country Link
US (1) US5508276A (pt)
EP (1) EP0693282B1 (pt)
JP (1) JP3707831B2 (pt)
KR (1) KR100356240B1 (pt)
CN (1) CN1106191C (pt)
AT (1) ATE200620T1 (pt)
AU (1) AU686384B2 (pt)
BR (1) BR9503346A (pt)
CA (1) CA2153856C (pt)
CO (1) CO4410177A1 (pt)
CZ (1) CZ288095B6 (pt)
DE (1) DE69520711T2 (pt)
DK (1) DK0693282T3 (pt)
ES (1) ES2157297T3 (pt)
GE (1) GEP20063944B (pt)
GR (1) GR3036185T3 (pt)
HU (1) HU221502B (pt)
IL (1) IL114584A (pt)
MY (1) MY116361A (pt)
NO (2) NO312397B1 (pt)
NZ (1) NZ272554A (pt)
PE (1) PE32196A1 (pt)
PL (1) PL181296B1 (pt)
PT (1) PT693282E (pt)
RU (1) RU2147231C1 (pt)
SI (1) SI0693282T1 (pt)
TW (1) TW382596B (pt)
UA (1) UA41344C2 (pt)
YU (1) YU49445B (pt)
ZA (1) ZA955799B (pt)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2227410A1 (en) * 1995-07-24 1997-02-06 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
AU746887B2 (en) 1998-09-15 2002-05-02 Eli Lilly And Company Treatment of persistent pain
EP1970052A2 (en) * 1999-02-09 2008-09-17 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
HRP20020729A2 (en) * 2000-03-07 2004-02-29 Lilly Co Eli Treatment of psoriasis
CA2442410A1 (en) * 2001-03-29 2002-10-10 Owen Brendan Wallace Duloxetine for treatment of hot flashes
ES2333645T3 (es) * 2001-06-22 2010-02-25 Bend Research, Inc. Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros.
CN1545421A (zh) * 2001-06-22 2004-11-10 �Ʒ� 包含低溶解度和/或酸敏感的药物以及中和的酸性聚合物的药物组合物
WO2004045606A1 (en) * 2002-11-19 2004-06-03 Eli Lilly And Company Treatment of gastrointestinal disorders with duloxetine
UY28431A1 (es) * 2003-07-24 2005-02-28 Smithkline Beecham Cororation Peliculas que se disuelven por via oral
WO2005097070A1 (ja) * 2004-04-08 2005-10-20 Kyowa Hakko Kogyo Co., Ltd. 安定性の向上した固形製剤およびその製造方法
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
EP1856087A1 (en) * 2005-03-08 2007-11-21 Teva Pharmaceutical Industries Limited Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
EP1858874A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. (s)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine-di-p-toluoyl-l-tartarate and methods of preparation thereof
EP1904039A2 (en) * 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
EP1915137B8 (de) 2005-08-10 2013-09-11 ADD Advanced Drug Delivery Technologies, Ltd. Orales präparat mit kontrollierter freisetzung
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
US20080207923A1 (en) * 2005-09-22 2008-08-28 Santiago Ini Pure DNT-maleate and methods of preparation thereof
US7842717B2 (en) * 2005-09-22 2010-11-30 Teva Pharmaceutical Industries Ltd. DNT-maleate and methods of preparation thereof
US20070155820A1 (en) * 2005-11-23 2007-07-05 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
EP1863782A1 (en) * 2005-12-05 2007-12-12 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphtol) thiophene, an imputity of duloxetine hydrochloride
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
MX2007011611A (es) * 2006-01-23 2007-10-18 Teva Pharma Fumarato de dnt y metodos de preparacion de ellos.
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
KR200416582Y1 (ko) 2006-03-07 2006-05-19 김정배 건강신발
JP2009538315A (ja) * 2006-05-22 2009-11-05 テバ ファーマシューティカル インダストリーズ リミティド 塩酸デュロキセチン遅延放出型製剤
WO2007139984A2 (en) * 2006-05-23 2007-12-06 Teva Pharmaceutical Industries Ltd. Duloxetine hcl polymorphs
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
CN101190208B (zh) * 2006-11-30 2011-11-02 石药集团中奇制药技术（石家庄）有限公司 一种含有盐酸度洛西汀的药物制剂及其制备方法
WO2008077645A1 (en) 2006-12-22 2008-07-03 Synthon B.V. Process for making duloxetine and related compounds
MX2009007057A (es) * 2006-12-27 2009-09-23 Lek Pharmaceuticals Composicion de duloxetina.
EP1938840A1 (en) * 2006-12-27 2008-07-02 LEK Pharmaceuticals D.D. Duloxetine composition
EP2018860A1 (en) * 2007-07-16 2009-01-28 LEK Pharmaceuticals D.D. Duloxetine composition
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
EP2150242A2 (en) * 2007-04-20 2010-02-10 Wockhardt Research Centre Pharmaceutical compositions of duloxetine
WO2009004649A2 (en) * 2007-05-21 2009-01-08 Sun Pharmaceutical Industries Limited Enteric coated pharmaceutical compositions
GB0712220D0 (en) * 2007-06-23 2007-08-01 Arrow Int Ltd Duloxetine formulation
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
EP2182929A2 (en) * 2007-07-13 2010-05-12 Synthon B.V. Duloxetine formulations
WO2009087657A2 (en) * 2007-11-03 2009-07-16 Alkem Laboratories Ltd. Stable pharmaceutical composition of duloxetine and process for its preparation
EP2240162A4 (en) 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
EP2231169B1 (en) * 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US20110070299A1 (en) * 2008-01-25 2011-03-24 Alphapharm Pty Ltd. Delayed release pharmaceutical composition of duloxetine
US20090226517A1 (en) * 2008-02-06 2009-09-10 Vinita Umashankar Vyas Pharmaceutical formulations comprising duloxetine
AU2009230676A1 (en) * 2008-03-24 2009-10-01 Lupin Limited Delayed release compositions of duloxetine
US20110038933A1 (en) * 2008-05-06 2011-02-17 Dexcell Ltd. Stable benzimidazole formulation
EP2133072A1 (en) 2008-06-13 2009-12-16 KRKA, D.D., Novo Mesto Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation
WO2010037849A1 (en) * 2008-10-02 2010-04-08 Laboratorios Del Dr. Esteve, S.A. Duloxetine enteric pellets
CN101756960B (zh) 2008-12-26 2012-06-27 上海中西制药有限公司 一种度洛西汀肠溶制剂及其芯材和制备方法
WO2010078878A1 (en) * 2009-01-12 2010-07-15 Synthon B.V. Duloxetine formulations
CA2765635C (en) * 2009-06-25 2016-09-06 Wockhardt Research Centre Pharmaceutical composition of duloxetine or pharmaceutically acceptable salts thereof
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
EP2477614A2 (en) * 2009-09-17 2012-07-25 Cadila Healthcare Limited Pharmaceutical compositions for reducing alcohol-induced dose dumping
DK2512455T3 (en) * 2009-12-18 2014-03-24 Frieslandcampina Nederland Holding B V Co-treated tablet adjuvant composition, its preparation and use
MX339408B (es) * 2010-03-09 2016-05-24 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas entericas resistentes al alcohol.
EP2377525A1 (en) * 2010-03-26 2011-10-19 Laboratorios del Dr. Esteve S.A. Duloxetine enteric pellets
WO2011148380A1 (en) * 2010-05-25 2011-12-01 Hetero Research Foundation Oral pharmaceutical composition of duloxetine
CN102908331A (zh) * 2011-08-01 2013-02-06 浙江九洲药物科技有限公司 一种盐酸度洛西汀肠溶胶囊及其制备方法
JOP20200144A1 (ar) 2012-04-30 2017-06-16 Tillotts Pharma Ag تركيبة عقار ذو إطلاق متأخر
WO2013164122A1 (en) 2012-05-02 2013-11-07 Capsugel France SAS Aqueous dispersions of controlled release polymers and shells and capsules thereof
CN103505421B (zh) * 2012-06-29 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种盐酸度洛西汀的肠溶微丸制剂
CN103211777A (zh) * 2013-03-31 2013-07-24 北京万全阳光医学技术有限公司 一种盐酸度洛西汀的药物制剂及其制备的方法
GR1008228B (el) * 2013-04-23 2014-06-16 "Φαρματεν Α.Β.Ε.Ε.", Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
EP2813218B1 (en) 2013-06-14 2022-08-24 Shin-Etsu Chemical Co., Ltd. Method for producing aqueous enteric coating liquid, solid preparation, and method for producing same
CN103393615B (zh) * 2013-07-24 2015-07-15 海南华益泰康药业有限公司 一种度洛西汀肠溶小丸及其制备方法
PL224543B1 (pl) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Dojelitowa tabletka duloksetyny
NZ747731A (en) 2013-10-29 2020-02-28 Tillotts Pharma Ag A delayed release drug formulation
US20160256399A1 (en) 2013-11-04 2016-09-08 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
JP6190080B2 (ja) * 2014-05-20 2017-08-30 ダウ グローバル テクノロジーズ エルエルシー エステル化セルロースエーテルを含むカプセル殻
AU2015305215A1 (en) * 2014-08-22 2017-04-06 Medipath, Inc. Compositions and methods for cannabinoid coatings for use in drug delivery
US10471152B2 (en) * 2014-08-29 2019-11-12 Capsugel Belgium Nv Colloidal dispersion comprising HPMCAS
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
US9668975B2 (en) 2014-10-14 2017-06-06 PharmaDax Inc. Method of preparing drug agglomerate
CN105726488B (zh) * 2014-12-08 2020-10-20 上海爱科百发生物医药技术有限公司 含有呼吸道合胞病毒抑制剂的肠溶微丸及其制备方法
KR101625344B1 (ko) 2015-12-21 2016-06-08 주식회사 유영제약 세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물
CN105534949A (zh) * 2016-01-06 2016-05-04 北京修正创新药物研究院有限公司 一种盐酸度洛西汀的肠溶微丸制剂
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP6815109B2 (ja) * 2016-06-23 2021-01-20 キョーリンリメディオ株式会社 デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物
JP6856326B2 (ja) * 2016-07-15 2021-04-07 富士化学工業株式会社 腸放出粒子組成物
CN106166144A (zh) * 2016-08-12 2016-11-30 海南合瑞制药股份有限公司 一种盐酸度洛西汀肠溶胶囊药物组合物
JP2018172361A (ja) * 2016-10-14 2018-11-08 大原薬品工業株式会社 光安定性を改善した、デュロキセチンを含有する固形製剤
US9839626B1 (en) 2016-12-14 2017-12-12 Sun Pharmaceutical Industries Limited Duloxetine sprinkles
JP7072431B2 (ja) * 2017-04-14 2022-05-20 富士化学工業株式会社 錠剤及びその製造方法
JP6972674B2 (ja) * 2017-06-06 2021-11-24 ニプロ株式会社 経口医薬製剤
JP2020029447A (ja) * 2018-06-25 2020-02-27 大原薬品工業株式会社 腸溶性高分子及び抗付着剤を含有する顆粒
CN115844846B (zh) * 2018-10-25 2025-08-05 上海上药中西制药有限公司 盐酸度洛西汀肠溶制剂、其主药层及其混悬液、其隔离层及其包衣液、及其制备方法
JP7050714B2 (ja) * 2019-04-04 2022-04-08 信越化学工業株式会社 腸溶性コーティング用組成物及び固形製剤の製造方法
JP2020189815A (ja) * 2019-05-23 2020-11-26 東和薬品株式会社 デュロキセチン製剤およびその安定化方法
US20220265659A1 (en) 2019-09-02 2022-08-25 Inserm (Institut National De La Santé Et De Al Recherche Médicale) Methods and compositions for treating pax6-deficiency related disease
WO2021126098A1 (en) * 2019-12-18 2021-06-24 Santa Farma İlaç Sanayi̇ A.Ş. Gastro-resistant pellet comprising duloxetine
WO2021126099A1 (en) * 2019-12-18 2021-06-24 Santa Farma İlaç Sanayi̇ A.Ş. An enteric coated pellet comprising duloxetine hydrochloride with optimized degrees of neutralization
WO2022115054A1 (en) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Enteric coated duloxetine compositions
CN116251078B (zh) * 2021-12-09 2025-12-19 河北以岭医药研究院有限公司 一种盐酸度洛西汀肠溶胶囊及其制备方法
WO2024117996A1 (en) * 2022-11-30 2024-06-06 Santa Farma Ilac Sanayii A.S. Bioequivalent oral pharmaceutical composition comprising duloxetine hydrochloride

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CH649216A5 (de) * 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
US5100592A (en) 1986-03-12 1992-03-31 Washington University Technology Associated, Inc. Method and apparatus for granulation and granulated product
US5019302A (en) 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04346930A (ja) * 1991-05-25 1992-12-02 Sumitomo Pharmaceut Co Ltd 安定なアスピリン腸溶錠
RU2024526C1 (ru) * 1991-10-08 1994-12-15 Институт органической химии Уральского отделения РАН 5h- 3,4,6,7- тетрагидро-10- метокси-5-метил-6- (1',1'- диоксидо-3'- мета- хлоранилино-4'- метокси- бензо [в] тиофен -7'-ил) -фуро[4,3,2-q] [3]бензазоцин, обладающий антидепрессивным действием
RU2024520C1 (ru) * 1991-10-08 1994-12-15 Институт органической химии Уральского отделения РАН 10-метокси-5- метил-6- (1',1'- диоксидо-2'- метахлорфенилазо -3'- гидрокси -4'-метоксибензо(в)тиофен- 7-ил) -5h-3,4,6,7- тетрагидрофуро [4.3.2-q] [3]бензазоцин, обладающий антидепрессивным действием
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis

Also Published As

Publication number Publication date
HU9502134D0 (en) 1995-09-28
GR3036185T3 (en) 2001-10-31
CZ288095B6 (cs) 2001-04-11
PL181296B1 (pl) 2001-07-31
PT693282E (pt) 2001-07-31
HUT72466A (en) 1996-04-29
MY116361A (en) 2004-01-31
NO952786L (no) 1996-01-19
JPH0840895A (ja) 1996-02-13
NO952786D0 (no) 1995-07-13
EP0693282B1 (en) 2001-04-18
KR960003722A (ko) 1996-02-23
GEP20063944B (en) 2006-10-10
UA41344C2 (uk) 2001-09-17
PL309588A1 (en) 1996-01-22
CA2153856C (en) 2005-05-10
DE69520711D1 (de) 2001-05-23
RU2147231C1 (ru) 2000-04-10
PE32196A1 (es) 1996-08-07
BR9503346A (pt) 1996-02-27
CN1128141A (zh) 1996-08-07
JP3707831B2 (ja) 2005-10-19
AU2505195A (en) 1996-02-01
SI0693282T1 (en) 2002-02-28
EP0693282A3 (en) 1996-12-18
NZ272554A (en) 1996-11-26
YU49445B (sh) 2006-03-03
CN1106191C (zh) 2003-04-23
CO4410177A1 (es) 1997-01-09
EP0693282A2 (en) 1996-01-24
KR100356240B1 (ko) 2002-12-26
DE69520711T2 (de) 2001-09-20
NO2005002I1 (no) 2005-02-28
YU48095A (sh) 1998-07-10
IL114584A0 (en) 1995-11-27
TW382596B (en) 2000-02-21
US5508276A (en) 1996-04-16
ZA955799B (en) 1997-01-13
HU221502B (en) 2002-10-28
ES2157297T3 (es) 2001-08-16
CA2153856A1 (en) 1996-01-19
ATE200620T1 (de) 2001-05-15
IL114584A (en) 1999-09-22
DK0693282T3 (da) 2001-05-07
AU686384B2 (en) 1998-02-05
CZ180595A3 (en) 1996-03-13
NO2005002I2 (no) 2009-10-05

Similar Documents

Publication Publication Date Title
NO312397B1 (no) Enteriske duloxetinpellets
CA2234826C (en) Fluoxetine enteric pellets
CA2038245C (en) Pharmaceutically useful micropellets
EP1228125A2 (en) Process for making aqueous coated beadlets
CN101939004A (zh) 度洛西汀的缓释药物组合物
JP2004525897A (ja) 医薬処方
WO2010080970A2 (en) Oral enteric antidepressant formulation
WO2011096953A1 (en) Oral antidepressant formulation with reduced excipient load
CN110420195A (zh) 盐酸度洛西汀肠溶制剂、其主药层及其混悬液、其隔离层及其包衣液、及其制备方法
IE83510B1 (en) Fluoxetine enteric pellets
MXPA98003636A (es) Granulos entericos de fluoxetina

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: YENTREVE; NAT. REG. NO/DATE: EU104280001 20040826; FIRST REG. NO/DATE: DE , 203496 20040812

Spc suppl protection certif: 2005002

Filing date: 20050201

Extension date: 20190811

Effective date: 20091005

MK1K Patent expired
SPCX Expiry of an spc

Free format text: PRODUCT NAME: DULOKSETIN

Spc suppl protection certif: 2005002

Effective date: 20190903